Insmed Inc. is a biopharmaceutical company based in Bridgewater, New Jersey, that specializes in developing innovative therapies for patients with rare and serious diseases, particularly in the realms of pulmonary and infectious diseases. The company's lead product, ARIKAYCE, offers a vital treatment for individuals with treatment-refractory Mycobacterium avium complex lung disease, highlighting its commitment to addressing significant unmet medical needs. With a robust pipeline and a strong emphasis on research and development, Insmed is well-positioned for growth and advancement, striving to improve health outcomes for patients with challenging conditions. Show more

Location: 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, UNITED STATES, 08807, Bridgewater, NJ, 08807, USA | Website: https://www.insmed.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

33.46B

52 Wk Range

$60.40 - $212.75

Previous Close

$156.87

Open

$156.63

Volume

2,612,320

Day Range

$150.80 - $156.86

Enterprise Value

32.52B

Cash

334.8M

Avg Qtr Burn

-219.8M

Insider Ownership

0.56%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BRINSUPRI™ (brensocatib) Details Non-Cystic Fibrosis Bronchiectasis	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TPIP (Treprostinil Palmitil Inhalation Powder) Details Pulmonary hypertension, Interstitial lung disease (PH-ILD)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TPIP (Treprostinil Palmitil Inhalation Powder) Details Pulmonary arterial hypertension (PAH)	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Brensocatib Details Hidradenitis suppurativa (HS)	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Brensocatib (DPP1 inhibitor) Details Cystic fibrosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INS1148 (SCF248 Antibody) Details Moderate-To-Severe Asthma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INS1148 (SCF248 Antibody) Details Interstitial Lung Disease	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INS1201 Details Duchenne muscular dystrophy (DMD)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Brensocatib (DPP1 inhibitor) Details Chronic rhinosinusitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.